Article Sidebar
Published:
Feb 13, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Curculigoside attenuates <i>Helicobacter pylori</i>-induced inflammation and apoptosis of gastric mucosal epithelial cells via NF-κB pathway
Abstract
Purpose: To investigate the possible effects and mechanisms of action of curculigoside (Cur) on gastric ulcers.
Methods: Human gastric mucosal epithelial GES-1 cells were infected with Helicobacter pylori and then treated with Cur. Cell counting kit 8 (CCK-8), flow cytometry, and immunofluorescence assays were used to investigate the effect of Cur on cell viability and apoptosis after exposure to H. pylori. Inflammation status and reactive oxygen species (ROS) were assessed using enzyme-linked immunoassay (ELISA) and dichlorodihydrofluorescein (DCF) staining, respectively, while immunoblot and immunofluorescence assays were performed to determine the effect of Cur on the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway.
Results: Cur significantly increased H. pylori-induced cell viability and inhibited H. pylori-induced inflammatory cytokine production (p < 0.01). Furthermore, Cur significantly suppressed H. pylori-induced ROS production and apoptosis (p < 0.01). Through the NF-κB pathway, Cur attenuated H. pylori-induced inflammation and apoptosis of gastric mucosal epithelial cells.
Conclusion: In H. pylori infection, Cur treatment increases cell viability, reduces inflammatory cytokine production, suppresses ROS production, and inhibits apoptosis via NF-κB pathway. Further investigation using whole animal experiments would be needed to establish the role of Cur in the management of H. pylori-induced gastric ulcers.
